ATE428932T1 - Diagnostische verwendung von scn2b für alzheimer erkrankung - Google Patents

Diagnostische verwendung von scn2b für alzheimer erkrankung

Info

Publication number
ATE428932T1
ATE428932T1 AT04707222T AT04707222T ATE428932T1 AT E428932 T1 ATE428932 T1 AT E428932T1 AT 04707222 T AT04707222 T AT 04707222T AT 04707222 T AT04707222 T AT 04707222T AT E428932 T1 ATE428932 T1 AT E428932T1
Authority
AT
Austria
Prior art keywords
scn2b
alzheimer
disease
diagnostic use
diagnostic
Prior art date
Application number
AT04707222T
Other languages
English (en)
Inventor
Der Kammer Heinz Von
Johannes Pohlner
Jozef Hanes
Original Assignee
Evotec Neurosciences Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Evotec Neurosciences Gmbh filed Critical Evotec Neurosciences Gmbh
Priority claimed from PCT/EP2004/000916 external-priority patent/WO2004070388A1/en
Application granted granted Critical
Publication of ATE428932T1 publication Critical patent/ATE428932T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Neurology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Neurosurgery (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
AT04707222T 2003-02-04 2004-02-02 Diagnostische verwendung von scn2b für alzheimer erkrankung ATE428932T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44466603P 2003-02-04 2003-02-04
PCT/EP2004/000916 WO2004070388A1 (en) 2003-02-04 2004-02-02 Diagnostic and therapeutic use of scn2b protein for neurodegenerative diseases

Publications (1)

Publication Number Publication Date
ATE428932T1 true ATE428932T1 (de) 2009-05-15

Family

ID=32852231

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04707222T ATE428932T1 (de) 2003-02-04 2004-02-02 Diagnostische verwendung von scn2b für alzheimer erkrankung

Country Status (3)

Country Link
JP (1) JP2006518199A (de)
AT (1) ATE428932T1 (de)
DE (1) DE602004020584D1 (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021197100A (ja) * 2020-06-18 2021-12-27 国立研究開発法人産業技術総合研究所 情報処理システム、情報処理方法、同定方法及びプログラム

Also Published As

Publication number Publication date
DE602004020584D1 (de) 2009-05-28
JP2006518199A (ja) 2006-08-10

Similar Documents

Publication Publication Date Title
DK1944040T3 (da) Analysefremgangsmåde for Alzheimers sygdom
DE502005002436D1 (de) Endochirurgischer bergebeutel für die aufnahme von körpergewebe oder -flüssigkeit
ATE550338T1 (de) Spiropiperidininhibitoren von beta-secretase zur behandlung von alzheimer-krankheit
DE60320860D1 (de) Super-elastische Titanlegierung für medizinische Verwendung
DE502004011497D1 (de) Chirurgisches Instrument
ATE426816T1 (de) Fruhdiagnose von konformationellen erkrankungen
DE60325770D1 (de) Verwendung von rimexolon zur behandlung von augentrockenheit
DE50209802D1 (de) Naht-set für medizinische zwecke
ATE314354T1 (de) Radiopharmazeutika für die diagnose von alzheimer
ATE504580T1 (de) Malonsäureamidderivate als inhibitoren von g- sekretase zur behandlung von alzheimer-krankheit
ATE452655T1 (de) Verwendung von l-polynukleotiden zur diagnostischen bilderzeugung
ZA200603178B (en) Quick test for the diagnosis of Alzheimer's disease
DE602004028071D1 (de) Halter - Anordnung für eine medizinische Naddle
DE502004005673D1 (de) Medizinisches Instrument
ATE310736T1 (de) Verbindungen zur bilddarstellung der alzheimer- krankenheit
FR2845267B1 (fr) Kit cutane de diagnostic de l'atopie
ITMI20041954A1 (it) "procedimento per stimare lapendenza longitudinale del piano stradale"
ATE428932T1 (de) Diagnostische verwendung von scn2b für alzheimer erkrankung
DE50212649D1 (de) Verwendung von desoxypeganin zur behandlung der klinischen depression
EP1769089A4 (de) Verfahren und zusammensetzungen für die prä- oder postsymptomatische diagnose von alzheimer und anderen neurodegenerativen erkrankungen
DE502004002460D1 (de) Verwendung von copolymerisaten als hilfsmittel für die lederherstellung
EP1832877A4 (de) Verfahren zur untersuchung von morbus alzheimer
AU2003236714A8 (en) Diagnosis of alzheimer's disease based on the habeta42:habeta40 ratio
ITMI20031790A1 (it) Antagonistici abiotici dell'eparina.
DE60235576D1 (de) Diagnostikum für die frühe phase von morbus alzheimer

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties